Strategic Appointment of Professor Randolph Noelle

Lead Research Organisation: King's College London
Department Name: Immunology Infection and Inflam Diseases

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
 
Description AICR
Amount £80,000 (GBP)
Organisation Association for International Cancer Research 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2013 
End 02/2015
 
Description Cognate Interaction of B lymphocytes
Amount $175,000 (USD)
Funding ID R37 AI26296 
Organisation National Institute of Allergy and Infectious Diseases (NIAID) 
Sector Public
Country United States
Start 03/2003 
End 02/2014
 
Description Wellcome Trust Principal Research Fellowship - New (The cellular and molecular basis for the impact of vitamin A on immunity)
Amount £4,750,000 (GBP)
Funding ID 091823 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2010 
End 07/2017
 
Title Retinoic Acid engineered mice 
Description We have produced mice in which retinoid acid synthesis can be manipulated. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2013 
Provided To Others? Yes  
Impact This mouse strain will uniquely be able to define lineages of cells that must make retinoid acid to support immunity 
 
Title VISTA antibodies and reagents 
Description Produced antibodies to both mouse and human VISTA and produced KO mice as well as conditional KO mice. 
Type Of Material Antibody 
Year Produced 2013 
Provided To Others? Yes  
Impact Allows investigation of a newly described molecule that we discovered in our lab in 2011. 
 
Description Development of VISTA therapeutics 
Organisation Janssen Biotech, Inc.
Department Oncology Discovery
Country United States 
Sector Private 
PI Contribution Systems to study the activity of new therapeutic antibodies specific to VISTA
Collaborator Contribution Expertise is development of fully human anti-human mabs
Impact Developing fully human anti-human mabs for clinical development.
Start Year 2011
 
Description Retinoic acid and regulatory T cell function 
Organisation King's College London
Department Transplantation Immunology & Mucosal Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution We have provided unique genetically engineered mouse models to study regulatory T cell function
Collaborator Contribution Dr Lombardi has the expertise to study regulatory T cell functions in transplantation
Impact None
Start Year 2013
 
Description Treg adoptive therapy 
Organisation King's College London
Department MRC Centre for Transplantation
Country United Kingdom 
Sector Academic/University 
PI Contribution Technology and knowledge concerning retinoic acid receptors
Collaborator Contribution High level interactions with the Lombardi/Lechler LabInteractions with Lord Lab
Impact Submission of a number of grant applications
Start Year 2010
 
Description Treg adoptive therapy 
Organisation King's College London
Department MRC Centre for Transplantation
Country United Kingdom 
Sector Academic/University 
PI Contribution Technology and knowledge concerning retinoic acid receptors
Collaborator Contribution High level interactions with the Lombardi/Lechler LabInteractions with Lord Lab
Impact Submission of a number of grant applications
Start Year 2010
 
Description VISTA 
Organisation King's College London
Department MRC Centre for Transplantation
Country United Kingdom 
Sector Academic/University 
PI Contribution Production of VISTA engineered proteins for future immunotherapy
Collaborator Contribution Provided expertise in protein biochemistry
Impact None as of yet
Start Year 2010
 
Description VISTA Structure 
Organisation King's College London
Department Centre for Ultrastructural Imaging
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided VISTA proteins for structural studies
Collaborator Contribution Analysis of structure of VISTA recombinant molecules
Impact Involvement of pharmaceutical interest in VISTA structure.
Start Year 2013
 
Description VISTA in inflammatory bowel disease 
Organisation King's College London
Department Transplantation Immunology & Mucosal Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution Produce VISTA-Ig molecules for therapy
Collaborator Contribution Test VISTA-Ig molecules in murine models of inflammatory bowel disease
Impact None
Start Year 2013
 
Description VISTA in kidney disease 
Organisation King's College London
Department Transplantation Immunology & Mucosal Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution We produce anti-VISTA mabs and VISTA-Ig for testing in kidney disease models.
Collaborator Contribution Partner is an expert in murine models of kidney disease and tests the impact of anti-VISTA and VISTA-Ig
Impact none
Start Year 2013
 
Title Compositions and Methods for Producing Adaptive Regulatory T Cells 
Description The present invention relates to a method for producing adaptive regulatory T cells from effector T cells by contacting the effector T cells with retinoic acid. Adaptive regulatory T cells produced by this method are Foxp3+, home to the gut, and are refractory to reversion in vivo. As such, such cells find application in the treatment of autoimmune disease and facilitating transplantation tolerance. 
IP Reference US2010183575 
Protection Patent granted
Year Protection Granted 2010
Licensed No
Impact The methods described will be useful for producing stable adaptive regulatory T cells for therapy in humans with autoimmune disease and for graft rejection
 
Title IMMUNOSTIMULATORY COMBINATIONS 
Description The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen. 
IP Reference US2011280903 
Protection Patent granted
Year Protection Granted 2011
Licensed Yes
Impact na
 
Title INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARa SELECTIVE AGONISTS 
Description The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection. 
IP Reference WO2012125749 
Protection Patent granted
Year Protection Granted 2012
Licensed Yes
Impact The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection.
 
Title REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF 
Description The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates aCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon aCD3/aGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed 
IP Reference US2012195894 
Protection Patent granted
Year Protection Granted 2012
Licensed Yes
Impact na
 
Title REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF 
Description The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates aCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon aCD3/aGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed 
IP Reference US2012301484 
Protection Patent granted
Year Protection Granted 2012
Licensed Yes
Impact Targetting this molecule (PD-L3, VISTA) will allow enhanced immune responses to tumors and enhance tumor rejection
 
Title Anti-VISTA Therapeutics in Oncology Licensing to JNJ Pharmaceuticals 
Description We have recently (Sept 2012) closed a $150 Million dollar milestone agreement with JNJ for the development of anti-VISTA mabs for the treatment of cancer. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2012
Development Status Under active development/distribution
Impact It is anticipated that anti-VISTA will have profound impact on the development of anti-tumor immunity in man. 
 
Title VISTA-Ig agonists for the treatment of autoimmunity (In final negotiation of licensing to Pharma) 
Description VISTA-Ig represents a new class of immunosuppressive drugs. We are in the final phases of term sheet agreements with large pharma for the development of this class of drugs. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2013
Development Status Actively seeking support
Impact We are currently in preclinical testing of VISTA-Ig in a variety of murine autoimmune models. Large pharma has expressed interest and we are in the final phases of licensing this new drug to pharma. 
 
Company Name ImmuNext 
Description In 2006 I co-founded ImmuNext and am currently CSO. The company is involved in developing biotherapeutics for autoimmunity and cancer. 
Year Established 2006 
Impact Licensing to JNJ a new antibody based therapeutic for cancer. Licensing >$150 M in milestones plus royalties. Also in the process of licensing VISTA-Ig as a novel therapeutic for the treatment of autoimmune disease.
Website http://www.immunext.com